Adaptive Biotechnologies Says Its Next-generation Sequencing-based clonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Adaptive Biotechnologies announced that its next-generation sequencing-based clonoSEQ test for measurable residual disease assessment will be featured in several presentations at the American Society of Clinical Oncology Annual Meeting and the European Hematology Association Hybrid Congress.
May 31, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adaptive Biotechnologies' clonoSEQ test will be featured in several presentations at major upcoming medical conferences, potentially increasing visibility and adoption of the test.
The inclusion of the clonoSEQ test in multiple presentations at high-profile medical conferences like ASCO and EHA can significantly boost the test's visibility and credibility among healthcare professionals, potentially leading to increased adoption and sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100